GH Research PLCGHRS
Price$22.86

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Dec 2025
Net Income -$48.3MTTM through 31 Dec 2025
Free Cash Flow -$43.7MTTM through 31 Dec 2025

Margins

Current

Returns

-17.3%ROE
-16.7%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio34.13x
Net Debt-$280.7Mnet cash position
Cash & Equivalents$246.3M

Quality Metrics

Piotroski F-Score2 / 9
Earnings-Beat Rate50.0%

Multi-Year Trend

Diluted EPS
'19'20'21'22'23'24'25
FY2025: $-0.79

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Research and Development$00.0%
View details

Actively seeking FDA alignment on the design of its global Phase 3 pivotal program, targeting initiation in late 2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.